Shifting to Direct U.S. Sales
Glenmark Pharmaceuticals will manage RYALTRIS®'s U.S. commercialization and distribution directly starting April 1, 2026. This marks a shift from its prior strategy, which included partnerships like Hikma Pharmaceuticals for distribution. Glenmark aims for greater control over brand strategy, market access, and customer engagement to better connect with healthcare providers and respond to market changes.
The Allergy Market Opportunity
The U.S. market for seasonal allergic rhinitis (SAR) was valued at about $3.6 billion in 2023 and is expected to grow. Major competitors like Sanofi, GSK, and AbbVie operate with large commercial teams. By bringing RYALTRIS® operations in-house, Glenmark will bear the full cost of building its own U.S. sales force, distribution network, and market access efforts. While direct control could improve profit margins by removing third-party fees, setting up this infrastructure requires significant upfront investment. For example, U.S. pharmaceutical sales representatives can cost $260,000 to over $450,000 annually. RYALTRIS® received FDA approval in January 2022. Following the announcement, the stock fell slightly to ₹2,131.70 on March 30, 2026, with the market capitalization at ₹60,557.50 crore. This suggests investors are considering the execution risks and substantial capital needed for this move.
Balancing Costs and Ambitions
This move aligns with a trend of drugmakers wanting more control over how their products reach the market. RYALTRIS®, a nasal spray combining olopatadine hydrochloride and mometasone furoate, targets the combination therapy segment of the allergy market. The global market for allergic rhinitis treatments is projected to reach $23.81 billion by 2032, with North America as a key region. Glenmark's expansion faces hurdles, including past regulatory issues affecting U.S. manufacturing and supply, and ongoing antitrust lawsuits against its U.S. subsidiary over generic drug pricing. The direct control model demands strong sales execution, plus thorough compliance and supply chain management, which are resource-heavy. Glenmark has developed its U.S. operations since 2005, and this direct sales model represents a major acceleration.
Risks and Financial Strain
Taking direct control of RYALTRIS®'s U.S. commercialization brings notable financial and operational risks. Building a specialized sales team and distribution network for an allergy nasal spray is costly. Glenmark's P/E ratio, between 40.4x and 56.5x as of March 2026, indicates investor expectations for growth. However, the large investment needed for this new sales model could hurt short-to-medium term profits. While Glenmark has steady growth from Europe and emerging markets, the U.S. market's intense competition and the cost of a direct presence may cut into profit margins. Past regulatory issues in the U.S. and ongoing antitrust cases against its U.S. unit add compliance and reputational risks. Competitors like Astepro Allergy also compete in the combination nasal spray market, meaning Glenmark must now gain physician and patient attention directly, without previous third-party marketing support. Although Glenmark is shifting toward innovation and branded products in areas like oncology and dermatology, a direct sales model for RYALTRIS® requires specific skills that may need further development. This could lead to slower market entry or higher spending to reach sales goals.
Outlook and Investor Views
Glenmark intends to use direct control to boost RYALTRIS®'s market standing, building on its approval in 55 countries by FY26. The company's North America business has grown, supported by injectables and partnered products, showing existing capability. Analyst views are divided; some rate the stock 'Strong Buy,' while others, such as ICICI Securities, recommend 'Reduce' with price targets below current levels. This reflects differing opinions on the company's growth outlook and valuation. The pivot's success depends on Glenmark's efficiency in building and running its U.S. commercial operations while managing market access and tough competition. Sustained growth in India and North America, along with its pipeline, will be key to offsetting the costs of direct sales efforts.